Q Chip, Ltd.: Series C $6M

Posted in I - Series C, Q - 2Q11, R - INTERNATIONAL, X - Endocrinology, X - Oncology

Q Chip (United Kingdom) a preclinical-stage biopharmaceutical company focused on sustained release formulations of oncology and endocrine therapeutics, closed a $6M Series C financing. Participants include Limburg Ventures and Nedermaas Hightech Ventures.

Versartis, Inc.: Series B $21M

Posted in I - Series B, Q - 1Q11, R - WEST, X - Endocrinology, X - Growth Deficiency, XX - CA

Versartis (Mountain View, CA) a clinical-stage biopharma company focused on growth hormone deficiency and additional endocrine disorders, closed a $21M Series B financing. Participants include Advent Venture Partners, Index Ventures and Amunix.

Syntaxin, Ltd.: Series C $28.3M

Posted in I - Series C, Q - 4Q10, R - INTERNATIONAL, X - Endocrinology, X - Oncology, X - Pain

Syntaxin (United Kingdom) a preclinical-stage biopharmaceutical company focusing on targeted secretion inhibitors for the potential treatment of pain, endocrine disease and cancer, closed a $28.3M Series C financing. Participants include Lundbeckfond Ventures, Ipsen, Seventure Partners, Abingworth, SROne, Life Science Partners, Johnson & Johnson Development Corp and Quest for Growth.

Aragon Pharmaceuticals, Inc.: Series B $22M

Posted in I - Series B, Q - 2Q10, R - WEST, X - Endocrinology, X - Oncology, XX - CA

Aragon Pharmaceuticals (San Diego, CA) a preclinical-stage stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer, closed a $22M Series B financing. Participants include Aisling Capital, OrbiMed and The Column Group.

Versartis, Inc.: Series A $11M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Diabetes, X - Endocrinology, X - Growth Deficiency, X - Metabolism, XX - CA

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

Dicerna Pharmaceuticals, Inc.: Series A $8.4M

Posted in I - Series A, Q - 3Q08, R - NORTH EAST, X - Diabetes, X - Endocrinology, X - Oncology, X - RNAi

Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.

to top of page...